Volkswagen revealed the Mission Efficiency, a prototype electric vehicle capable of achieving an equivalent of 323 miles per gallon under ideal conditions. The car was driven 794 miles from Wolfsburg to Vienna on a single charge plus a partial recharge, demonstrating real-world efficiency of about 279 MPGe. Its aerodynamic design and lightweight materials contribute to its high efficiency, though compromises include limited rear seating and a low ride quality. While near production-ready, Volkswagen has not confirmed plans for mass production yet.
Volkswagen's Mission Efficiency electric vehicle is noted here alongside Pluang's Consumer Cyclical sector data for context. For readers following this sector, here is Pluang's market snapshot as of Sep 14, 2026 23:31 WIB: out of 105 US stocks, 69 rose and 36 fell. Macy's Inc (M) led with a 3.65% gain at USD 22.89, closely followed by Li Auto Inc (LI) up 3.64% at USD 12.24, and Best Buy Co Inc (BBY) increased 3.54% to USD 94.01.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
